Member Info for Barnacle

I'm not sure what you were expecting, as the the August pre-close trading statement gave a good indication of Q3 revenue? Revenues for the year shoud be around £11million, Market cap now £12million, so looking cheap. Streamlining the business is a positive, as LBE is clearly the Growth driver here.

A good choice in Feedback Medical PrivateRyan, it's going to do very well IMHO. But so will CPX.....;0)

Mole Valley Asset Management Ltd

now 6.15%

I think that why the share price hasn't reacted is because their cash burn is so high at the moment, so they may still need a placing in the not too distant future?

We're exciting to announce we will be at the Amazon Web Services (AWS) Roadshow in Cardiff on November 10th! This half day event will bring together healthcare, government, and technology leaders to focus on unlocking the value of healthcare data.

Join Dr Thomas Oakley to hear about how we can achieve cross-provider care through a common view of patient data.

"In terms of the Maxwell case, CAP-XX has secured an offer for litigation funding which is expected to soon be in place to cover the legal fees in FY23, subject to the completion of due diligence from the litigation funder. The litigation offer ensures the counterparty understands that the case will be pursued indefinitely if needed and at no cost to CAP-XX. For a case to even receive an offer of litigation funding., this is a sign that the case is seen as being strong."

Like this bit:

"Furthermore, it notes that it has litigation funding approved, pending completion of due diligence process, which will put pressure on Maxwell to settle."

And AVX royalties resuming.

Cenkos Buy Recommendation now up to 14p. :0)

What I find most exciting is that there is an ever increasing sales pipeline, with new products that have recently been added to the portfolio, that haven't impacted these historical results. These being the Lithium Ion Hybrid supercapacitors, the TruckStart units and the Power modules. Then there is the 3Volt products which are coming on line in a few months:

"The first 3 Volt products from Seven Hills are expected to ship to customers by the end of this calendar year. The development of the 3 Volt product has been targeted to meet demand for small, inexpensive, energy efficient power solutions for thin wearables, key FOBs and other IoT devices, especially those using 3 Volt coin cell lithium ion batteries, such as the CR2032 battery."

And then there are the cylindrical supercapacitors:

"In the past, CAP-XX has faced competition in various markets from cheaper cylindrical supercapacitors where our thin form factor, high power and long life are not valued as highly as lower initial cost components from competitors. To counteract this, the Company released a range of cylindrical cells. Modest sales revenue for these products was first recorded during FY 2019. Since then, sales have continued to grow strongly, with the Company being successful in winning significant large volume orders. Several new large volume opportunities are currently being evaluated by customers."

And not forgetting the DMF, DMT and DMH products:

"The Board remains of the view that the installation of the additional production facilities at the Seven Hills facility is transformational for the Company's sales and profitability. The capacity of the Seven Hills plant is around 4.8 million DMF or DMT products per year and more than 2.4 million DMH products per year. Operations at Seven Hills have continued to improve in yield, costs and output as expected. Production costs are currently more than 50% lower than the prismatic parts which the Company manufactures in Malaysia. These production costs are expected to decrease further as further improvements are commissioned. At Seven Hills, the Company is well advanced in obtaining the German automotive quality accreditation VDA6.3 which the Board considers necessary for expanding sales in automotive applications."

"Dotpost is your secure online document hub, enabling you to store and organise any document important to you on any of your devices, keeping them safely in the cloud to access them where and when you need them."

"Dotpost works with the organisations sending you appointment letters, bills, statements and more to help them switch from printing and posting documents to delivering electronic documents to your Dotpost inbox.

"Bleepa is the only CE/UKCA accredited medical app that allows you to share, annotate and discuss clinical grade images on a mobile device."

https://bleepa.com//wp-content/uploads/2021/10/Bleepa__fact-sheet.pdf

I suggest that you go to the Bleepa.com website, and make your own mind up. Would be interested to know what you think.

Looks like Carelocker has it's own Domain Name.

https://carelocker.in/

Good point, over 20% higher, so should have a positive impact on Revenue.

Revenue from Location Based Entertainment for the whole of last year was £6.3million. From the trading statement in August '22: "unaudited LBE revenue for the seven months to 31 July 2022 to £5.7m" so almost the same as the previous year with another 5 month trading to go! Bodes well for the rest of the year.

Unaudited revenue at the Group's core Location Based Entertainment ("LBE") business for H1 2022 almost doubled to £4.4m (from £2.3m in H1 2021).

In addition, the LBE business is currently enjoying very strong trading in the key summer period, with unaudited July 2022 revenue of £1.3m being the division's best ever month. This takes unaudited LBE revenue for the seven months to 31 July 2022 to £5.7m, a 78% increase from £3.2m in the equivalent period in 2021.

August 2022 has also started very strongly.

R&D Cash Rebate payment of A$2million due in a few months, all helps.....

• Adjusted EBITDA* Loss of A$0.3 million (2020: Profit of A$0.3 million)
• Revenue up 14% up on corresponding prior year period
• Product sales up 40% driven by IoT markets
• No Royalty or licence income reported in the period
• Sales order book at end CY 21 more than 40% higher than same time CY 20
• Sales pipeline now in excess of US$50m p.a.
• Aggregate level of customer enquiries well exceeds nominal capacity
• Increasing interest from global multinational companies
• Ramp up of production and capacity expansion continuing to plan
• CAP-XX is vigorously pursuing Maxwell for patent infringement and AVX for breach
of patent licence agreement.

Nice to hear this:

"A lot of demand is moving from smaller companies to Global multinationals who have some very interesting projects in the pipeline."

A reminder from the pre-close trading statement:

The Board is encouraged by the outlook for FY23 and beyond and expects to see continued strong growth in product sales. This growth is being driven by increasing customer demand for DMF and DMT products, cylindrical supercapacitors and traditional supercapacitor products made in Malaysia. In addition new products, such as LICs together with the expansion of our distribution channels are expected to increase sales.

Both court cases are progressing favourably and the Board, under advice from our lawyers, remains confident of the Company's prospects of securing a favourable outcome. This has enabled the Board to secure litigation funding which is expected to be in place to cover the legal fees in FY23.

Even if the revenues predicted for this year which were £8million are not met, look at the valuation of the company now, crazy!!

No, they have an agreement with Accelerated Payments Limited:

The Group had a cash balance as at 30 June 2022 of £0.7m (30 June 2021: £1.4m) and no bank debt.

We are pleased to announce that the Group has entered into a receivables financing agreement with Accelerated Payments Limited. This highly flexible facility has been put in place to provide working capital funding, as and when required, as we look to grow the business over the coming months and years.

This is now ridiculously low!